Skip to main content
The Journal of Biological Chemistry logoLink to The Journal of Biological Chemistry
. 2010 Aug 25;285(45):34850–34863. doi: 10.1074/jbc.M110.167668

Pseudomonas aeruginosa Homoserine Lactone Activates Store-operated cAMP and Cystic Fibrosis Transmembrane Regulator-dependent Cl Secretion by Human Airway Epithelia*

Christian Schwarzer , Steven Wong , James Shi , Elizabeth Matthes , Beate Illek §, Juan P Ianowski , Ryan J Arant , Ehud Isacoff , Horia Vais , J Kevin Foskett , Isabella Maiellaro **, Aldebaran M Hofer **, Terry E Machen ‡,1
PMCID: PMC2966100  PMID: 20739289

Abstract

The ubiquitous bacterium Pseudomonas aeruginosa frequently causes hospital-acquired infections. P. aeruginosa also infects the lungs of cystic fibrosis (CF) patients and secretes N-(3-oxo-dodecanoyl)-S-homoserine lactone (3O-C12) to regulate bacterial gene expression critical for P. aeruginosa persistence. In addition to its effects as a quorum-sensing gene regulator in P. aeruginosa, 3O-C12 elicits cross-kingdom effects on host cell signaling leading to both pro- or anti-inflammatory effects. We find that in addition to these slow effects mediated through changes in gene expression, 3O-C12 also rapidly increases Cl and fluid secretion in the cystic fibrosis transmembrane regulator (CFTR)-expressing airway epithelia. 3O-C12 does not stimulate Cl secretion in CF cells, suggesting that lactone activates the CFTR. 3O-C12 also appears to directly activate the inositol trisphosphate receptor and release Ca2+ from the endoplasmic reticulum (ER), lowering [Ca2+] in the ER and thereby activating the Ca2+-sensitive ER signaling protein STIM1. 3O-C12 increases cytosolic [Ca2+] and, strikingly, also cytosolic [cAMP], the known activator of CFTR. Activation of Cl current by 3O-C12 was inhibited by a cAMP antagonist and increased by a phosphodiesterase inhibitor. Finally, a Ca2+ buffer that lowers [Ca2+] in the ER similar to the effect of 3O-C12 also increased cAMP and ICl. The results suggest that 3O-C12 stimulates CFTR-dependent Cl and fluid secretion in airway epithelial cells by activating the inositol trisphosphate receptor, thus lowering [Ca2+] in the ER and activating STIM1 and store-operated cAMP production. In CF airways, where CFTR is absent, the adaptive ability to rapidly flush the bacteria away is compromised because the lactone cannot affect Cl and fluid secretion.

Keywords: Calcium Intracellular Release, Cyclic AMP (cAMP), Cystic Fibrosis, Epithelium, Fluorescence Resonance Energy Transfer (FRET), Innate Immunity, Lung

Introduction

The Gram-negative, opportunistic bacterium Pseudomonas aeruginosa commonly infects lungs of cystic fibrosis (CF)2 patients and triggers innate immune responses of airway epithelial cells, including activation of NF-κB and p38 signaling and increased secretion of cytokines and chemokines that recruit white cells, primarily neutrophils, to the infected region. When CF patients become colonized with P. aeruginosa, the bacteria secrete quorum-sensing molecules, including N-(3-oxo-dodecanoyl)-S-homoserine lactone (3O-C12) and butyryl homoserine lactone, to signal each other and to regulate their own gene expression, including genes involved in formation of biofilms (16). Concentrations of 3O-C12 in CF sputum are thought to be in the nanomolar range (7) but reach 5 μm in P. aeruginosa supernatants and may reach >100 μm in regions adjacent to biofilms (8, 9).

In addition to its effects as a quorum-sensing gene regulator in P. aeruginosa, 3O-C12 elicits cross-kingdom effects to alter signaling and responses of multiple cell types, including human cells. 3O-C12 operates through TLR- and Nod/Ipaf/caterpillar-independent signaling to activate multiple proinflammatory genes that are associated with NF-κB signaling, including IL8, Cox2, and MUC5AC in both epithelial and other cell types (712). Some of these proinflammatory effects may be mediated through activation of MAPKs (8, 9) or Ca2+ (7, 13) or inhibition of peroxisome proliferator-activated receptor γ (14). However, 3O-C12 also inhibits NF-κB signaling and expression of proinflammatory cytokines in macrophages and primary human bronchial airway epithelial cells (9) when cells are treated with both 3O-C12 and another agonist like LPS or TNFα that activates NF-κB on its own. Thus, 3O-C12 appears to stimulate proinflammatory responses on its own but inhibit responses when present with other proinflammatory agonists.

The goals of this study were to determine the effects of 3O-C12 on Cl secretion by airway epithelia, the role for CFTR in this secretion, and whether Ca2+ and cAMP signaling were involved. 3O-C12 increases cytosolic [Ca2+] (Cacyto) in fibroblasts (7) and mast cells (13), and at least at high [3O-C12] (250–1000 μm), this resulted from Ca2+ release from an internal store, possibly the endoplasmic reticulum (ER). If 3O-C12 elicited similar effects in airway epithelia, 3O-C12 might also raise cAMP by an ER store-operated cAMP mechanism recently described for colonic epithelial cells; Lefkimmiatis (15) discovered that thapsigargin (inhibitor of the Ca2+-ATPase of the ER) activated cAMP production by releasing Ca2+ from the ER, lowering [Ca2+] in the ER (CaER), and activating the ER-resident protein STIM1 (stromal interacting molecule 1; Ref 16) and adenylate cyclase.

The present experiments used electrophysiological and imaging methods to test whether the store-operated cyclase model (15) could explain the stimulatory effects of 3O-C12 on Cl secretion by airway epithelia. Transepithelial electrophysiology was used in combination with CFTR-expressing and genetically matched airway epithelial cell lines to test whether 3O-C12 increased CFTR-dependent Cl secretion. Fluid secretion by submucosal glands in intact pig tracheas was measured to determine whether 3O-C12-stimulated Cl secretion also contributed to fluid secretion in intact tissues. Cacyto (fura-2 imaging) and CaER (FRET imaging of ER-targeted cameleon) were measured during treatments with 3O-C12 and thapsigargin (selective blocker of Ca2+-ATPase in the ER) to test whether increases in Cacyto resulted from release of Ca2+ from the ER or from some other organelle. Patch clamp electrophysiology of inositol trisphosphate receptor 1 (IP3R1) expressed in the nuclei isolated from chicken B cells (DT40) tested whether decreases in CaER resulted from direct 3O-C12 activation of the IP3R or some other release or uptake mechanism. Total internal reflection fluorescence (TIRF) imaging was used to measure activation of STIM1, the key ER protein that has been proposed to mediate reductions in CaER to activation of cAMP production (15). The role of cAMP in the Cl secretory response was tested by measuring cAMP with Epac H30 FRET imaging and then by testing inhibitors that increase [cAMP] (phosphodiesterase blocker) and inhibit protein kinase A (Rp)-cAMP. Finally, cAMP and Cl secretion were measured in cells treated with the membrane-permeant ER Ca2+ buffer TPEN to determine whether specific reductions in CaER (i.e. without altering Cacyto) would increase cAMP and activate Cl secretion.

MATERIALS AND METHODS

Reagents

Unless otherwise specified, all reagents and chemicals were obtained from Sigma. 3O-C12 (Cayman Chemical, Ann Arbor MI) was dissolved in ethanol and frozen in separate vials and then thawed for single experiments. Preliminary experiments showed that 3O-C12 lost potency with repeated thaw-freeze-thaw cycles. The cAMP-elevating agonist forskolin (Calbiochem) was prepared as a 20 mm stock solution in dimethyl sulfoxide (DMSO), and an aliquot was added at final concentrations of 2–50 μm. CFTR blocker glibenclamide (17) was prepared as a 300 mm stock solution in DMSO and added to solutions at 1 mm. GLYH101 (18) and CFTRinh172 (19) were provided by Dr. Alan Verkman (University of California, San Francisco), prepared as a 20 mm stock solution in DMSO, and added to solutions at concentrations noted in the text. The Ca2+-ATPase blocker thapsigargin (20) was prepared as a 1 mm stock in DMSO and used at 5 μm. TPEN was added to Ca2+-free Ringer's containing 100 μm EGTA or Cl-free + Ca2+-free Ringer's at 1 mm and dissolved by continuous stirring for 1 h. TPEN was then used at either 1 or 0.5 mm as mentioned specifically in the text.

Tissue Culture

CaLu-3 cells, a normal human airway epithelial cell line expressing high levels of CFTR (21), were cultured in either Dulbecco's modified Eagle's (DMEM) or Eagle's minimum essential media supplemented with 10% FBS, 2 mm l-glutamine, and 1% penicillin/streptomycin. Cystic fibrosis airway cells JME (also called CF15), a continuous SV40 large T antigen-transformed human nasal epithelial cell line homozygous for ΔF508 CFTR, were cultured in Dulbecco's modified Eagle's medium/F-12 media supplemented with 10% FBS, 2 mm l-glutamine, 1% penicillin/streptomycin, 10 ng/ml EGF, 1 μm hydrocortisone, 5 μg/ml insulin, 5 μg/ml transferrin, 30 nm triiodothyronine, 180 μm adenine, and 5.5 μm epinephrine. For some experiments, cells were passaged at a 1:2–1:5 dilution, and the remaining cell suspension was seeded directly onto 24-well plates or 30-mm diameter dishes for cyclic AMP assays. For electrophysiological experiments, CaLu-3 cells were passaged onto 1.12-cm2 permeable polycarbonate supports (0.4 μm pore size, Snapwell, Corning Costar, Lowell, MA) and grown until cells formed confluent monolayers. Cultures were maintained at 37 °C in a humidified atmosphere of 5% CO2 and 95% air. CaLu-3 cells routinely had transepithelial resistance greater than 400 watts·cm2 and exhibited polarized responses consistent with previous studies (21, 22).

The role of CFTR in Cl secretory responses to 3O-C12 was determined by comparing CF and CFTR-corrected CF bronchial cell lines. The parent human bronchial CF (CFBE41o, ΔF508/ΔF508) and CFTR-corrected (CFTR-CFBE41o) cell lines were generated and cultured on permeable supports as described previously (23, 24). Both the parental CFBE41o and the CFTR-corrected CFBE41o cell lines consistently maintained an epithelial phenotype and expressed Ca2+-activated Cl currents but no amiloride-sensitive Na+ absorption. The CFTR-CFBE41o clone maintained a high level of transgene expression over all observed passages (23) and exhibited forskolin-stimulated Cl secretion.

Transepithelial Electrophysiology

For measurements of transepithelial Cl current, CaLu-3 cell monolayers were grown on permeable supports, washed in PBS, mounted into water-jacketed (37 °C) Ussing chambers (Physiologic Instruments, San Diego), and used for electrophysiological studies (2224). Transepithelial voltage (Vt), resistance (Rt), and short circuit current (ISC) were measured using typical four-electrode voltage clamp with Ag/AgCl electrodes (World Precision Instruments, Sarasota, FL) connected to the solutions through agar bridges containing 1 m KCl. Positive currents were defined as cation movement from mucosa to serosa or anion movements in the opposite direction. Chamber compartments were separately perfused with 5 ml of Krebs-Henseleit solutions. A serosal-to-mucosal Cl gradient was used to increase the electrochemical driving force for Cl secretion across the apical membrane. The basolateral solution contained (in mm) the following: 120 NaCl, 25 NaHCO3, 5 KCl, 1.2 NaH2PO4, 5.6 glucose, 2.5 CaCl2, and 1.2 MgCl2. The mucosal Cl-free solution contained (in mm) the following: 120 sodium gluconate, 20 NaHCO3, 5 KHCO3, 1.2 NaH2PO4, 5.6 glucose, 2.5 Ca(gluconate)2, and 1.2 MgSO4. Solutions were gassed with 95% O2 and 5% CO2 resulting in pH 7.4. Cl-free + Ca2+-free Ringer's had the same composition as the Cl-free Ringer's but omitted Ca2+. Transepithelial ISC measured under these conditions was termed ICl.

Optical Measurement of Mucous Fluid Secretion from Pig Tracheal Submucosal Glands

Methods for isolating and preparing tracheas for measurements of fluid secretion were similar to those published previously (2528). Briefly, trachea and lungs were obtained from carcasses of 6–9-week-old Yorkshire pigs used for acute experiments. No pigs were sacrificed for the present experiments. Procedures for care and euthanization of pigs were approved by the Animal Research Ethics Board at the University of Saskatchewan. Pieces of trachea or bronchus (∼0.5 cm2) were pinned mucosal side up, and the mucosa with underlying glands was dissected from the cartilage and mounted in a Sylgard-lined Petri dish, with the serosa in the bath (∼1 ml volume), the mucosa in air, and maintained at 35–37 °C and high humidity, using a TC-324 single channel heater and DH-35i dish incubator (Harvard Apparatus, Saint-Laurent, Quebec, Canada). Cotton swabs and air-drying were used to clean and dry the tissue surface, and 20–30 μl of water-saturated mineral oil were placed on the surface. The tissue was superfused with warmed, humidified 95% O2, 5% CO2. 3O-C12 was diluted to final concentration with warmed, gassed bath solution and added to the serosal side by complete bath replacement; the maximal DMSO concentration in the preparation was <0.1%.

Droplets of fluid + mucus within the oil layer were visualized by transillumination, and images were captured using a digital camera (MiniVid USB, LWScientific, Lawrenceville, GA) mated to a 1× ocular of a stereomicroscope. Each image contained an internal reference grid to compensate for minor adjustments in magnification during the experiment. Secretion volumes were calculated as described previously using the formula: V = 4/3(π r3), where r is radius (26).

To be included in the analysis, each droplet had to meet the following criteria: (a) circular outline so that a spherical shape could be assumed; (b) clear edges to allow accurate measurement of the radius; and (c) no fusion with neighboring droplets. Viability was tested at the end of each experiment by measuring the response to carbachol (1 μm); glands that did not respond to carbachol were excluded from the analysis. Although the majority of the submucosal glands was quiescent before stimulation, some produced fluid spontaneously as they were warmed from room temperature and then became quiescent again by the time they reached 37 °C. Consequently, the initial fluid volume observed at 37 °C was subtracted from those measured during the last 10 min, and the net (subtracted) volumes were plotted and used to calculate secretion rates. The secretion rate was calculated by fitting the volume versus time plots with straight lines using linear regression, and slopes were taken as the secretion rates expressed in nl min−1. Linear regressions were performed using at least four points, and the r2 value was>0.8.

Patch Clamp Measurements of IP3 Receptor Activity in Nuclei Isolated from DT40 Cells

DT40 cells with all three InsP3R isoforms genetically deleted (DT40-InsP3R-KO) (29) stably expressing the rat type-3 InsP3R channel (DT40-KO-r-InsP3R-3 cells) were washed twice with PBS and suspended in a nuclear isolation solution containing 150 mm KCl, 250 mm sucrose, 1.5 mm 2-mercaptoethanol, 10 mm Tris·HCl, 0.05 mm PMSF, and protease inhibitor mixture (Roche Applied Science), pH 7.3. Preparation of isolated nuclei from cells was performed as described (3032). Nuclei were studied in standard bath solution (in mm) as follows: 140 KCl, 10 HEPES, 0.5 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, and 0.192 CaCl2 (free [Ca2+] = 90 nm). The pipette solution contained (in mm) the following: 140 KCl, 10 HEPES, 0.5 ATP, 0.5 dibromo-,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid, and 2 μm free Ca2+, pH 7.3. Free [Ca2+] in solutions was adjusted by Ca2+ chelators with appropriate affinities and confirmed by fluorometry as described previously (31). Data were recorded at room temperature and acquired using an Axopatch 200A amplifier (Axon Instruments) under voltage clamp (Vm = −40 mV), filtered at 1 kHz, and digitized at 5 kHz with an ITC-16 interface (Instrutech) and Pulse software (HEKA Electronik). Single-channel Po analysis was performed using the QuB software (State University of New York, Buffalo).

Measuring Cacyto Using Fura-2 Imaging Microscopy

Cells grown on cover glasses were incubated with growth media containing 2 μm fura-2/AM for 40–60 min at room temperature and then washed three times with Ringer's solution to remove the extra dye. The Ringer's solution had the following composition (in mm): 145 NaCl, 5 KCl, 1.2 NaH2PO4, 5.6 glucose, 1.0 CaCl2, 1.2 MgCl2 and 10 mm HEPES, pH 7.4. Ca2+-free Ringer's omitted CaCl2 and included 100 μm EGTA.

Fura-2-loaded cells were mounted onto a chamber on the stage of the imaging microscope and maintained at room temperature. Treatments with agonists were made by diluting stock solutions into Ringer's solution at the concentrations stated in the text. Fluorescence ratio imaging measurements of cytosolic Ca2+ (Cacyto) were performed using equipment and methods that have been reported previously (3335). Briefly, a Nikon Diaphot inverted microscope was used with a 40× NeoFluar objective (1.4 NA). A CCD camera collected emission (>510 nm) images during alternate excitation at 350 ± 5 and 380 ± 5 nm using a filter wheel (Lambda-10, Sutter Instruments, Novato, CA). Axon Imaging Workbench 4.0 (Axon Instruments, Foster City, CA) controlled both filters and collection of data. Images were corrected for background (region without cells). Data have been reported as 380:350 ratio, a measure of Cacyto (36).

Measuring cAMPcyto and CaER Using Genetically Targeted FRET Imaging Microscopy

A genetically encoded cAMP sensor was used for single cell imaging of cAMP (15, 37, 38). This sensor (CFP-Epac(∂ DEP-CD)-YFP; called “Epac H30”) is a monomeric construct that relies on FRET between YFP- and CFP-labeled portions of the cAMP-binding protein, Epac1 (38). Upon cAMP binding, the Epac probe undergoes a conformational change that alters the intermolecular distance between the fluorophores, reflected by a change in FRET. Epac H30 has been modified to be catalytically inactive against its normal target, repressor activator protein (Rap1), and is also missing domains required for membrane association, rendering it an inert, soluble probe for cytosolic cAMP. The methods used for measuring cAMP have been described previously (15, 37). Subconfluent cultures of CaLu-3 epithelial cells were grown on glass coverslips and transfected with Epac H30 using Effectene (Qiagen, Valencia, CA). After 24–48 h, coverslips were mounted in a perfusion chamber on the stage of a Nikon TE2000 inverted microscope. Fluorescence images of cells expressing the sensor were acquired using Metafluor (Universal Imaging). Excitation pulses (440 nm) were generated using a microprocessor controlled filter wheel (Sutter Instruments, Novato, CA) and mercury light source. Pairs of fluorescence images collected alternately at 480- and 535-nm wavelengths were captured (Hamamatsu ORCA ER CCD camera) every 4 s and converted to a ratio image using the Metafluor software. FRET was expressed as ratio of CFP to YFP signals (480:535 nm). Cells were treated at the end of each experiment with 50 μm forskolin + 1 mm isobutylmethylxanthine (IBMX) to yield maximal [cAMP], and 480:535 ratios were compared with these maxima to yield relative increases in [cAMP] during treatments with 3O-C12 and forskolin.

ER luminal Ca2+ (CaER) was measured using the FRET-based D1ER cameleon (39). This probe has Kd(Ca2+) = 60 μm, suitable for measurements of CaER (39, 40). Subconfluent cultures of CaLu-3 epithelial cells were grown on glass coverslips and transfected with a plasmid coding for D1ER as described above. After 24–72 h, coverslips were mounted onto a chamber on the stage of a Nikon Diaphot microscope as described for fura-2 measurements above. The CCD camera collected alternate emission 530:470 nm images during excitation at 430 nm (S430/25×, S470/30-m and S535/30-m filters from Chroma Technology, Bellows Falls, VT), controlled by Axon Imaging Workbench 4.0. All images were corrected for background (region without cells). Changes in CaER were expressed as the YFP-to-CFP emission ratio (530:470 nm).

STIM1 Activation Measured with TIRF Microscopy

JME cells were plated on cover glasses and incubated in growth media for 24 h before co-transfection with STIM1-GFP and CD8-tagRFP. Cells were allowed to express for 48 h before experiments were performed. Total internal reflection fluorescence measurements were made to exclude fluorescence from the ER, and CD8-tagRFP was utilized to focus exclusively on the cell plasma membrane and ensure that the focal plane did not change during the course of the experiment. EGFP and tagRFP were alternately excited at 0.1 Hz by a 488-nm argon laser and 532-nm DPSS laser, respectively. Fluorescence emissions of GFP (525/50-nm bandpass filter, Chroma) and tagRFP (592/50-nm bandpass filter, Chroma) were acquired by an EMCCD camera (Andor iXon DV-897 BV) with 500-ms exposure per frame. Base-line images were acquired in standard Ringer's solution for 5 min before 10 μm 3O-C12 (final concentration) was pipetted into the imaging chamber. 20 min after adding 3O-C12, 2 μm thapsigargin (final concentration) was added, and images were taken for an additional 10 min. Fluorescence intensities were analyzed offline with ImageJ.

Statistics

Unpaired or paired t tests, Mann-Whitney test, and nonparametric repeated measurements, ANOVA and Dunn's multiple comparison test, were used to compare groups and effects, depending on the experiments; p < 0.05 was considered significant. Data have been presented as values from individual experiments or as averages ± S.D. unless otherwise stated; n refers to the number of experiments.

RESULTS

3O-C12 Stimulates CFTR-dependent Cl Secretion in Airway Epithelial Cell Monolayers

3O-C12 was tested for effects on Cl secretion by adding it to the apical side of CaLu-3 cells grown on filter inserts in Ussing chambers. Concentrations of 3O-C12 between 1 and 100 μm were tested. To normalize the responses, cells were also treated with the adenylate cyclase activator forskolin to increase cytosolic cAMP and activate maximal rates of Cl secretion. 10 μm 3O-C12 caused, after a variable delay, slow increases in ICl over the course of 45 min (Fig. 1A). These increases in ICl were accompanied by decreases in Rt, as shown by the increases in size of current pulses required to clamp transepithelial voltage from 0 mV (short circuit) to 1 mV, consistent with activation of Cl channels (and Cl secretion) in the cells. As also shown in Fig. 1A, subsequent treatment with a maximal dose of the adenylate cyclase activator forskolin (10 μm) caused a further increase in ICl. ICl stimulated by 3O-C12 was largely blocked by the CFTR-specific inhibitor CFTRinh172 (Fig. 1A), indicating that the 3O-C12-stimulated ICl was likely dependent on the activity of CFTR. Further addition of the less selective CFTR blocker glibenclamide (or GLYH101, not shown) caused ICl to decrease nearly to the initial value (Fig. 1A), indicating that there may have been another channel besides CFTR contributing to the ICl response. These results also showed that these responses resulted from Cl movements through the cells and not through tight junctions.

FIGURE 1.

FIGURE 1.

3O-C12 stimulates ICl in CaLu-3 cell monolayers. A, typical experiment (of >10 experiments) showing effects on ICl (μA/cm2) by adding 10 μm 3O-C12, 10 μm forskolin, and CFTR blockers CFTRinh172 (50 μm) and glibenclamide (Glib) (1 mm) to the apical solution of Calu-3 cells in Ussing chambers with Cl-containing basolateral solution and Cl-free apical solution. The small pulsed increases in ICl show changes resulting from transiently clamping Vt to −1 mV to calculate Rt. 3O-C12 caused ICl to increase from 6 to 14 μA/cm2 over 45 min. Forskolin caused a further rapid increase to 25 μA/cm2. CFTRinh172 reduced ICl, and glibenclamide caused a further reduction. B, summary showing average (± S.D.) normalized ICl responses (compared with maximal ICl measured in presence of 10–20 μm forskolin) to different [3O-C12], n = 2–14 experiments at each [3O-C12]. *, p < 0.05 versus control.

Concentrations of 3O-C12 between 10 and 50 μm caused significant increases in ICl that amounted to 50–75% of ICl stimulated by forskolin (Fig. 1B). However, responses to these concentrations had large standard deviations, and although there was a trend to larger ICl at higher [3O-C12], there were no significant differences in ICl activated by 10, 15, 25, or 50 μm 3O-C12. There were no effects of 1 μm 3O-C12 on ICl or Rt. Experiments testing different [3O-C12] in single experiments were unsuccessful because responses to 3O-C12 were so slow that it was impossible to obtain traditional dose-response characteristics.

The specific role of CFTR in ICl responses was tested using the CF cell line CFBE41o and the stable CFTR-complemented CFBE41o cell lines. 3O-C12 (Fig. 2, A–C) stimulated ICl that was blocked by the CFTRinh172 in CFTR-corrected CFBE41o cells, but there was only a small or nonexistent stimulation of ICl in the CF cells (CFBE41o). Results of experiments using the CFTR inhibitors and the CF versus CFTR-corrected airway epithelial cells showed that CFTR was mediating almost all of the Cl secretion triggered by 3O-C12.

FIGURE 2.

FIGURE 2.

3O-C12 stimulation of ICl in CFBE41o cell monolayers requires CFTR expression. A and B, typical experiments showing ICl of CFTR-corrected CFBE41o and CFBE41o cells during control conditions and during treatment with 3O-C12 (10 μm, apical side) and then with CFTRinh172. C, averages ± S.E. (n = 6–10) of ICl measured during steady state control, 3O-C12, and 3O-C12 + CFTRinh172 for CFTR-CFBE41o and CFBE41o. *, p < 0.05 for comparison of 3O-C12 with control; #, p < 0.05 for comparison of CFTR-corrected CFBE41o versus CFBE41o.

3O-C12 Increases Fluid Secretion by Pig Tracheal Glands

The effect of 3O-C12 on native tissue was tested on pig airway submucosal glands. Preliminary experiments showed that submucosal glands did not respond consistently to 50 μm 3O-C12, whereas 100 μm 3O-C12 caused consistent stimulation. Experiments on intact airway submucosal glands therefore used 100 μm 3O-C12. Fluid secretion was measured from images of surface droplets (Fig. 3A, inset). Typical time courses of fluid accumulation at the surfaces of nine glands from one piece of trachea are shown in Fig. 3A. There was no fluid secretion from any of these glands during 10 min of control measurements. 3O-C12 increased volume of bubbles with variable size (2–13 nl) during the first 10–15 min, after which there were no further increases. Subsequent addition of carbachol (1 μm) to the bath caused a further rapid increase in fluid accumulation in the bubbles, showing that the response to 3O-C12 was less than maximal as induced by this potent secretagogue. On average, the secretion rate during 10 min of control incubation was 0.04 ± 0.01 nl min−1; 3O-C12 increased this rate to 0.37 ± 0.09 nl min−1 (mean ± S.E., 35 glands, 10 trachea preparations, p < 0.05 for comparison of 3O-C12 with control, Mann-Whitney Test), a rate that was 10 and 25% of the maximal secretion rates reported for the secretagogues carbachol and vasoactive intestinal peptide, respectively (28). Average results from 10 different preparations from four pigs are summarized in Fig. 3B. Because there was considerable scatter in the volumes of individual droplets, the average increase in volume did not reach statistical significance until 12 min following 3O-C12 addition.

FIGURE 3.

FIGURE 3.

3O-C12 stimulates fluid secretion by pig tracheal glands. A, fluid secretion versus time by 9 glands in one piece of trachea treated with 3O-C12 (100 μm) and then carbachol (1 μm) to ensure responsiveness. 3O-C12 increased fluid secretion during the first 10–15 min following application. Carbachol increased fluid accumulation further. Inset, typical images showing four droplets on the surface of the same airway region just before and then 18 min after adding 3O-C12 (100 μm) to the bath. B, volume accumulation before and after stimulation with 3O-C12 (mean ± S.E., 35 glands, 10 trachea preparations). *, significant difference from time 0 (p < 0.05).

3O-C12 and Thapsigargin Increase ICl and Cacyto in CaLu-3 Cells

The role of Cacyto in mediating increases in Cl secretion was tested by measuring ICl during treatments with 3O-C12 and also with thapsigargin (inhibits ER Ca2+ pump) to induce maximal release of Ca2+ from the ER. By comparing responses to 3O-C12 and thapsigargin, we also tested the role of ER Ca2+ in contributing to the 3O-C12-induced Cacyto response. We tested 10 and 50 μm 3O-C12; 10 μm was the lowest [3O-C12] that elicited increases in ICl, and 50 μm was expected to elicit a larger effect. Results from experiments measuring Cacyto in CaLu-3 cells grown on cover glasses and ICl responses of CaLu-3 cells grown on filters to 10 or 50 μm 3O-C12 and 5 μm thapsigargin are shown in Fig. 4. 10 μm 3O-C12 caused a small, slow increase in fura-2 ratio, and thapsigargin caused a faster, larger increase (Fig. 4A). 50 μm 3O-C12 caused a larger but still slow increase in fura-2 ratio; following 50 μm 3O-C12, there was only a small response to thapsigargin (Fig. 4B). When cells were treated first with thapsigargin, there were rapid, large, and transient increases in Cacyto, and 50 μm 3O-C12 had no further effect on Cacyto (Fig. 3C). An implication of these results was that 10 μm 3O-C12 released a portion of the ER Ca2+ store, 50 μm 3O-C12 released most of the store, and thapsigargin released all of the Ca2+ store.

FIGURE 4.

FIGURE 4.

Effects of 3O-C12 and thapsigargin Cacyto and ICl in CaLu-3 cells. Cacyto responses (excitation ratio, 350:385 nm) of fura-2-loaded cells in the imaging microscope (A–C) and ICl responses (Ussing chambers) (D–F) were measured during treatment with 10 μm 3O-C12, then 5 μm thapsigargin (A and D) and 50 μm 3O-C12 followed by 5 μm thapsigargin (B and E) or thapsigargin followed by 50 μm 3O-C12 (C and F). Results are typical of 3–6 experiments each.

Effects of 3O-C12 and thapsigargin on ICl were similar to the effects on Cacyto. 10 and 50 μm 3O-C12 both caused small, slow increases in ICl (Fig. 4, D and E). Subsequent addition of thapsigargin caused a further increase in ICl in cells treated with 10 μm 3O-C12 (Fig. 4D) but had almost no effect on cells that had been treated with 50 μm 3O-C12 (Fig. 4E). When cells were treated first with thapsigargin, there were rapid, large, and transient increases in ICl (Fig. 4F), but 25 μm 3O-C12 caused a further activation of ICl (by average of 16.7 ± 3.2 μA/cm2, n = 3) in thapsigargin-treated monolayers, indicating a Ca2+-independent component. Overall, these results indicated that 3O-C12 increased Cacyto in CaLu-3 cells by releasing Ca2+ from the thapsigargin-releasable pool of Ca2+ in the ER, consistent with previous measurements in fibroblasts (7) and macrophages (13).

3O-C12 Lowers CaER in CaLu-3 Cells

Previous experiments on fibroblasts showed that 250–1000 μm 3O-C12 caused equivalent increases in Cacyto in both Ca2+-containing and Ca2+-free solutions, indicating that 3O-C12 was releasing Ca2+ from internal stores (7). Similar results were obtained here for CaLu-3 cells grown on cover glasses as follows: 50 μm 3O-C12 caused small, slow increases in Cacyto in both Ca2+-containing (Fig. 4) and Ca2+-free solutions (data not shown). This 3O-C12-induced increase of Cacyto could have resulted from the Ca2+ release from the ER or from the mitochondria or other organelles. The role of the ER in the Cacyto response was tested by measuring CaER in CaLu-3 cells that were grown on cover glasses, transfected with ER-targeted cameleon D1 (3941), and imaged during treatment with 3O-C12 and thapsigargin. As shown in Fig. 5A, cameleon D1 appeared to be localized to the ER throughout the cell. As shown in Fig. 5B, cameleon FRET 530:470 ratio (proportional to CaER) was reduced in a dose-dependent manner by 3O-C12, with a small effect at 10 μm and a larger effect at 50 μm. Subsequent addition of a maximal concentration of thapsigargin (10 μm) caused a further small reduction of CaER. As shown in Fig. 5C, when cells were treated first with thapsigargin, there was a large drop in CaER, and subsequent addition of 50 μm 3O-C12 had no further effect. A summary of the effects of 3O-C12 and thapsigargin on CaER is shown in Fig. 5D. Similar results were obtained in the CF nasal cell line JME/CF15, and in these experiments 50 and 100 μm had similar effects on CaER, indicating that 50 μm gave a maximal response (data not shown). These experiments showed that 3O-C12 released Ca2+ from the thapsigargin-releasable pool of Ca2+ in the ER in a dose-dependent fashion. Maximal release of Ca2+ by 50 μm 3O-C12 was slightly less than that released by 10 μm thapsigargin.

FIGURE 5.

FIGURE 5.

3O-C12 lowers CaER and measurements in CaLu-3 cells using ER-targeted cameleon D1. A, typical confocal image (excitation 514 nm, emission 525–565 nm) of cameleon D1ER expressed in CaLu-3 cells. B, typical measurement of 530:470 FRET ratio (excitation 430 nm) in cells treated (arrows) with 10 and then 50 μm 3O-C12 followed by 10 μm thapsigargin (Tg) and finally with ionomycin + Ca2+-free solution to elicit maximal reduction in CaER. C, cells were treated with thapsigargin, 50 μm 3O-C12, 10 μm thapsigargin and ionomycin + Ca2+-free solution. D, average changes (± S.E.) in steady state 530:470 cameleon FRET ratio responses to 10 and 50 μm 3O-C12, 10 μm thapsigargin, and ionomycin-Ca2+-free solutions. *, p < 0.05 for comparisons to control (n = 6).

3O-C12 Activates the IP3 Receptor in the ER Nuclear Membrane of DT40 Cells

The 3O-C12-induced release of Ca2+ from the ER could have resulted from an effect to inhibit the Ca2+ pump/ATPase and/or from an effect to activate Ca2+ release through the IP3 receptor or other leak pathways in the ER. The functional consequences of 3O-C12 were explored by recording single IP3R channels in native ER membranes by patch-clamp electrophysiology of outer membranes of nuclei isolated from DT40-KO-r-IP3R-3 cells, as described previously (32, 42). The pipette solution, to which the cytoplasmic face of the channels faced, contained 1 μm IP3, 2 μm Ca2+, and 0.5 mm ATP, suboptimal conditions that result in channel open probability (Po) ≈0.05 (typical traces in Fig. 6A, summary in Fig. 6B). Addition of 10 μm C12 to the pipette solution enhanced channel activity by ∼5-fold (Po = 0.27 ± 0.05). Channel activity was further enhanced by 100 μm C12 (Po = 0.36 ± 0.05), comparable with that activated by 1 μm Bcl-xL (Po = 0.47 ± 0.04), a potent activator of the IP3R (32). In contrast, 100 μm C12 was without effect in the absence of IP3 (Fig. 6B). These data suggest that C12 activates IP3R channel gating by enhancing sensitivity of the channel to low levels of IP3.

FIGURE 6.

FIGURE 6.

3O-C12 activates IP3R channel and patch clamping IP3R1 in isolated nuclei of IP3R1-transfected DT40 cells. Nuclei from DT40 cells expressing only IP3R1 were isolated into a chamber for patch clamping (see “Materials and Methods”). Patch pipette was voltage-clamped to −40 mV; IP3R1 channel openings are shown by downward deflections of current records (closed channel, zero current shown by arrows). A, typical record from untreated, control IP3R is shown in the top panel and from IP3R with patch pipette containing 100 μm 3O-C12 is shown in the bottom panel. B, average (± S.E.) of Po for IP3R1 in the presence of the indicated concentrations of 3O-C12 or Bcl-xL. Note the Po for pipette containing 3O-C12 but no IP3 was near zero. Numbers adjacent to the bars are the number of different measurements for each treatment. *, p < 0.05 for comparisons to control.

3O-C12 Activates STIM1 in JME/CF15 Cells

Based on experiments in intestinal cells, Lefkimmiatis (15) proposed that reductions in CaER activate the ER resident protein STIM1, which associates with the plasma membrane and activates adenylate cyclase and production of cAMP. We tested whether the 3O-C12-induced release of Ca2+ from the ER resulted in activation of STIM1 and activation of cAMP production in airway epithelial cells. We used JME/CF15 cells for most of these studies because transfections with plasmids yielded more consistent expression in these cells. Similar results were obtained with CaLu-3 cells (data not shown).

JME/CF15 cells grown on cover glasses and transfected with STIM1-GFP showed ER-like expression throughout the cell (Fig. 7). STIM1-GFP migration to the plasma membrane was then measured using TIRF microscopy to assess STIM1 activation. Control cells showed only a few bright STIM1 puncta at the plasma membrane (Fig. 8A). 10 μm 3O-C12 caused an increase in bright membrane-localized STIM1 puncta over the course of 10–15 min (Fig. 8B). A further addition of 2 μm thapsigargin caused a further increase in bright STIM1 puncta at the cell membrane (Fig. 8C). Quantitation of the time courses of these responses was performed by measuring total TIRF fluorescence during the treatments (Fig. 8D); 3O-C12 caused an increase in steady state TIRF-measured STIM1 fluorescence, and this was further increased by thapsigargin. The transient increases followed by reductions in TIRF fluorescence after each change of condition likely resulted at least in part from bleaching of the GFP associated with exposure to the laser excitation. Control experiments showed that these transients did not result from changes in fluid volume resulting from additions to the chamber.

FIGURE 7.

FIGURE 7.

STIM1 localizes to the ER of JME/CF15 cells. JME/CF15 cells grown on cover glasses were transfected with a STIM1-GFP chimera plasmid and then examined 2 days later in the fluorescence microscope (excitation 490 nm, emission 520–560 nm). Focus in the middle of the nucleus showed STIM1 expressed throughout the ER. Image typical of >10 similar transfections.

FIGURE 8.

FIGURE 8.

3O-C12 activates STIM1 migration to the plasma membrane, and TIRF microscopy in stim1-GFP-expressing JME/CF15 cells. TIRF images of STIM1-GFP in two cells under control conditions (A), after 10 min treatment with 10 μm 3O-C12 (B), and after a further addition of 2 μm thapsigargin and 10 min (C). Time course of TIRF fluorescence during these treatments (D) showed that 3O-C12 caused slow increase in STIM1 migration to the membrane, and this was further increased by thapsigargin. Results typical of seven similar experiments. a.f.u., arbitrary fluorescent units.

3O-C12 Increases cAMPcyto in CaLu-3 Cells

3O-C12-induced increases in CFTR-dependent Cl secretion were consistent with 3O-C12 stimulating cAMP/PKA-activating CFTR (43, 44). ELISA-based assays were used in initial studies to measure cAMPcyto. Although low [forskolin] (100–200 nm) rapidly stimulated small increases in ICl (similar in magnitude to those activated by 3O-C12), there were no detectable changes in cAMP content using this method. We reasoned that the ELISA method was insufficiently sensitive to measure small changes of cAMPcyto that may occur with 3O-C12. We therefore performed single cell measurements of cAMPcyto using the FRET-based cytosolic sensor for cAMP, Epac H30. Expressed Epac H30 was distributed throughout the cytosol of CaLu-3 cells grown on cover glasses (Fig. 9A). 3O-C12 (33 μm; n = 19) produced a slow but significant (p < 0.001) increase in the Epac H30 480:535 nm emission ratio (a measure of cytosolic [cAMP]). As shown in Fig. 9B, this effect of 3O-C12 was smaller than that elicited by a submaximal concentration of forskolin (2 μm; ratio change following 3O-C12 was 32.2 ± 4.8% of forskolin, n = 12; p < 0.0001) and much less (22.9 ± 3.6%) than that produced by a supramaximal stimulation with forskolin (50 μm) + IBMX (1 mm; n = 16; p < 0.0001). The average changes in ratio (absolute value) for the treatments (±S.E.) are summarized in Fig. 9C. Overall, these experiments showed that 3O-C12 increased cytosolic [cAMP], but these increases were slightly smaller than those elicited by 2 μm forskolin and much smaller than those elicited by forskolin + IBMX.

FIGURE 9.

FIGURE 9.

3O-C12 increases cAMPcyto in CaLu-3 cells and measurements using Epac H30 FRET imaging. A, confocal image of Epac-transfected Calu-3 cell (excitation 514 nm, emission 525–565 nm) showed uniform distribution of the sensor throughout the cytoplasm and apparent exclusion from the nucleus. B, typical results (of 16 similar) showing 3O-C12 (33 μm) caused a small, slow increase in 480:535 emission ratio (indicating increased [cAMP]), and subsequent addition of forskolin (Fsk) (2 μm; a submaximal dose) and forskolin (50 μm) + IBMX (1 mm) caused further increases. C, summary of average changes in Epac 480:535 nm emission ratio (±S.E., n = 7–19) during treatments with 3O-C12 or 2 μm forskolin compared with maximal stimulation using 50 μm forskolin + 1 mm IBMX. *, p < 0.01 compared with control.

A further test of the role of cAMP in mediating 3O-C12-stimulated ICl was to incubate CaLu-3 cell monolayers grown on filters with reagents to either decrease or increase 3O-C12-triggered cAMPcyto. ICl responses to 3O-C12 were first measured in the presence of the selective cAMP antagonist (Rp)-Br-cAMPS. CaLu-3 cells were left untreated (control) or treated with (Rp)-Br-cAMPS (50 μm) for 12 h prior to treatment with 3O-C12 (10 μm). 3O-C12 (Fig. 10A) alone triggered typically small, slow increases in ICl. Subsequent treatment with forskolin caused rapid increases followed by a reduction to a secondary, elevated plateau. Treatment with (Rp)-Br-cAMPS reduced responses to 3O-C12 and 3O-C12 + forskolin (Fig. 10B; summary in Fig. 10C).

FIGURE 10.

FIGURE 10.

(Rp)-Br-cAMPS inhibits ICl in CaLu-3 cell monolayers stimulated by 3O-C12 and forskolin. A and B, typical experiments show ICl during treatment with 3O-C12 (10 μm) followed by forskolin (Fsk) (10 μm) (A) or similar treatments following treatment with 50 μm (Rp)-Br-cAMPS (B). C, average ICl measured in control and (Rp)-Br-cAMPS-treated cells in the presence of 3O-C12 or 3O-C12 + forskolin. Averages (± S.D.) of n = 3–4 experiments for all comparisons. *, p < 0.05 compared with controls; #, p < 0.05 (Rp)-Br-cAMPS compared with no (Rp)-Br-cAMPS. Glib, glibenclamide.

We also treated CaLu-3 cells with 100 μm IBMX to block phosphodiesterase and potentially augment any 3O-C12-induced stimulations of cAMP production. Cells were treated with 3O-C12 (10 μm) before or after IBMX. As shown in Fig. 11A, 3O-C12 caused typically slow increases in ICl, and addition of IBMX caused a further rapid increase in ICl. When IBMX was added first (Fig. 11B), there was a rapid increase in ICl followed by a decrease to plateau. In the presence of IBMX, 3O-C12 caused a faster and larger response than occurred in the absence of IBMX. In the presence of both 3O-C12 and IBMX, forskolin (10 μm) caused only a small increase in ICl, consistent with the idea that 3O-C12 + IBMX had elicited near maximal effects. A summary of the stimulatory effects of IBMX on 3O-C12-induced rate of increase of ICl in control versus IBMX-treated cells is summarized in Fig. 11C. The more rapid stimulatory effect of 3O-C12 on ICl in the presence of IBMX was consistent with the idea that IBMX was facilitating the stimulatory effect of 3O-C12. As summarized in Fig. 11D, there was no significant synergism in magnitudes of steady state responses between IBMX and 3O-C12, i.e. sum of the steady state ICl responses to 3O-C12 (50%) + IBMX (42%) were approximately equal to ICl stimulated by 3O-C12 + IBMX (92%) or by IBMX + 3O-C12 (93%), indicating that 3O-C12 may have been eliciting its effects on ICl mostly through effects on cAMP.

FIGURE 11.

FIGURE 11.

Effects of IBMX on 3O-C12-stimulated ICl of CaLu-3 cell monolayers. Cells were treated with 3O-C12 (10 μm) before or after adding IBMX (100 μm). These treatments were followed by forskolin (Fsk) (10 μm). A, 3O-C12 was added before IBMX (typical of six experiments). B, IBMX was added before 3O-C12 (typical of six experiments). C, summary of effects of 3O-C12 on rate of increase of ICl in control (as in A) versus IBMX-treated (as in B) condition. Slope of ICl versus time (μA/cm2/min) was measured during the first 5 min of 3O-C12 treatment in control (3O-C12 alone) versus IBMX pretreatment (3O-C12 + IBMX) following initial 3O-C12-induced transients that occurred in some cases (see B) in the two conditions. Data are averages (±S.D., n = 6). *, p < 0.05 for comparison with control; #, p < 0.05 for comparison with IBMX + 3O-C12. D, summary of effects of 3O-C12 versus 3O-C12 + IBMX and of IBMX versus IBMX + 3O-C12. Averages (±S.D., n = 6) of ΔICl expressed as percent of change from control measured during 3O-C12 + IBMX + forskolin. ΔICl (% forskolin) = (ICl (condition) − ICl (control))/(ICl(3O-C12 + IBMX + forskolin) − ICl(control)) × 100. *, p < 0.05 for comparison to 3O-C12; #, p < 0.05 for comparison to IBMX.

TPEN Increases cAMPcyto and ICl in CaLu-3 Cells

Previous experiments on intestinal cells showed that the high Kd Ca2+ chelator TPEN (Kd(Ca2+) = 130 μm) lowered CaER and stimulated cAMP production without altering Cacyto (15). Similar tests were used in airway epithelial cells. Epac H30-transfected CaLu-3 cells grown on cover glasses were incubated in Ca2+-free solution and treated with 1 mm TPEN. TPEN caused a slow increase in cAMPcyto that was ∼40% of the maximum triggered by forskolin + IBMX (Fig. 12A). A summary of the effects of 1 mm TPEN on cAMPcyto is shown in Fig. 12B. Further experiments showed that treatment of CaLu-3 cells with ionomycin in Ca2+-free solution, which also lowers CaER (Fig. 5), caused slow increases in cAMPcyto similar to those activated by TPEN (1 mm).3

FIGURE 12.

FIGURE 12.

TPEN increases cAMPcyto in CaLu-3 cells. A, Epac H30-transfected CaLu-3 cells were used for measurements of cAMPcyto. Typical experiment showing cAMPcyto when cells were incubated in Ca2+-free solution, then Ca2+-free + 1 mm TPEN, and finally with forskolin (Fsk) + IBMX. B, effects of TPEN on cAMPcyto, expressed as percent of the maximal 480:535 emission ratio measured in the presence of forskolin + IBMX at the end of the experiments (average ± S.D. n = 4). *, p < 0.05 compared with control; #, p < 0.05 compared with TPEN.

Because lowering CaER with 3O-C12, TPEN, or ionomycin increased cAMPcyto, it was predicted that TPEN would also stimulate ICl. CaLu-3 monolayers grown on filters were mounted in chambers with normal Ringer's in the basolateral solution and Ca2+-free and Cl-free apical solution so that TPEN could be added apically. As shown in Fig. 13A, 0.5 mm TPEN in the apical solution caused a slow increase in ICl similar to that triggered by 3O-C12. Subsequent addition of 50 μm 3O-C12 and then forskolin caused further small increases. The activated ICl was blocked by CFTRinh172, indicating a CFTR requirement. When 3O-C12 was added first (Fig. 13B), there was a typically slow increase in ICl, and further addition of TPEN and forskolin caused further small increases. The rapid increase in ICl when TPEN was added after 3O-C12 was consistent but unexplained. A summary of average steady state ICl in the different conditions is shown in Fig. 13C. TPEN and 3O-C12 elicited similar increases in ICl, and effects of TPEN + 3O-C12 were less than additive of the effects of adding TPEN or 3O-C12 individually.

FIGURE 13.

FIGURE 13.

TPEN and 3O-C12 elicit similar stimulation of ICl in CaLu-3 cell monolayers. CaLu-3 cells in Ussing chambers had Cl-containing Ringer's on the basolateral side and Cl-free + Ca2+-free Ringer's on the apical side. A, cells were treated with 0.5 mm TPEN followed by 10 μm 3O-C12, 20 μm forskolin (Fsk), and 10 μm CFTRinh172. B, cells were treated with 3O-C12, TPEN, forskolin, and CFTRinh172. C, average ICl (±S.D., n = 3–6 for each condition) measured in control conditions and then in the presence of TPEN, 3O-C12, TPEN + 3O-C12, TPEN + 3O-C12 + forskolin, and TPEN + 3O-C12 + forskolin + CFTRinh172. *, p < 0.05 for comparison to control; #, p < 0.05 for comparison with 3O-C12 or TPEN.

DISCUSSION

3O-C12-activated Cl and Fluid Secretion Requires CFTR Expression

A major conclusion of these experiments is that 3O-C12 stimulated CFTR-dependent Cl secretion in airway epithelia. Consistent with this finding in the serous-like CaLu3 cell line, 3O-C12 also stimulated fluid secretion by pig tracheal submucosal glands. The results indicated that 3O-C12-stimulated Cl secretion was accompanied by osmotically obliged fluid secretion from the glands, sites of a major fraction of the airway surface liquid in the upper airways (25, 27, 28). The secretion assay used for the present experiments does not test the role of tracheal surface cells in the response to 3O-C12, and further experiments will be needed to test this hypothesis.

Rates of fluid secretion measured optically in intact tissues in response to 100 μm 3O-C12 were ∼10–25% of maximal rates, consistent with the electrophysiological measurements showing that 3O-C12-stimulated currents were also less than (50–75%) of maximal rates (Fig. 1A). The need to use 100 μm 3O-C12 to generate a fluid secretion response in the tracheal preparation indicated that intact tissue was less sensitive to 3O-C12 compared with tissue culture cells, which responded to [3O-C12] as low as 10 μm. Although the precise [3O-C12] found in vivo remains unknown, the high lipid solubility of this molecule may ensure its equilibration into and action on cells throughout the epithelial surface in intact lungs that have been infected with P. aeruginosa.

3O-C12-stimulated Cl secretion was inhibited by CFTR blockers in CaLu-3 cells and occurred in CFTR-corrected CFBE41o but not CFBE41o cells. 3O-C12-stimulated ICl values were smaller than those elicited by high [forskolin] (2–10 μm), often used to maximally stimulate CFTR in airway epithelia. These data indicated that 3O-C12 was activating CFTR-dependent Cl secretion in airway epithelia. It has been argued (22) that airway epithelial Cl secretion stimulated by bacterial products is an important aspect of the innate immune response in the lung airways. Fluid accumulation on the airway surface in response to 3O-C12 and other bacterial products should facilitate flushing of bacteria on the mucociliary escalator. This bacterial flushing would be largely absent in CF, but effects on other secretions, e.g. mucus (45) and IL8 (10), would be retained (34). This condition could lead to both decreased bacterial clearance and also increased white cell influx, thereby contributing to the apparent hyperinflammatory phenotype observed in CF (46).

3O-C12 Activates IP3R, Lowers CaER, and Increases Cacyto

A second major conclusion from our experiments is that 3O-C12 activated the IP3R, decreased CaER, and increased Cacyto, showing that 3O-C12-stimulated increases in Cacyto resulted largely from IP3R-mediated release of Ca2+ from the ER. Patch clamp measurements showed that 3O-C12 increased open times of IP3R3 in nuclear membranes of DT40 cells. DT40 cell nuclei were an appropriate model for these experiments because responses could then be attributed to IP3R3. Because channel activity was measured in isolated nuclei where local activation of IP3 was unlikely, the results indicated a direct stimulatory effect of 3O-C12 on the IP3R, perhaps through an allosteric activation. If 3O-C12 increased the sensitivity of the IP3R to IP3, this would enable the IP3R to become more active under conditions of low [IP3] (0.2 μm) that may exist constitutively in unstimulated cells. It was notable that the stimulatory effect of 3O-C12 was large as follows: 10 μm 3O-C12 increased Po to ∼0.3 (5–6-fold over resting level) and 100 μm increased Po to ∼0.4, although maximal [IP3] increased Po of IP3R3 to ∼0.75 (31).

3O-C12 activation of IP3R in DT40 cell nuclei was consistent with cameleon D1ER FRET measurements in CaLu-3 cells showing that 10 μm 3O-C12 released ∼20% and 50 μm 3O-C12 ∼85% of ER Ca2+ that was released by thapsigargin. These results indicated that in CaLu-3 cells 3O-C12 opened IP3R, increasing Ca2+ leak from the ER and reducing CaER, even though the Ca2+-ATPase of the ER was still operating. When cells were treated with thapsigargin prior to 3O-C12, CaER was reduced to a low level (and Cacyto was increased) so that 3O-C12 had little or no further effect on either CaER (or Cacyto). 3O-C12-induced reductions in CaER explain why 3O-C12 elicited Cacyto responses in Ca2+-free solutions.

Previous experiments on fibroblasts showed that an inhibitor of phospholipase C blocked effects of 3O-C12 to elevate Cacyto, indicating that 3O-C12 was releasing Ca2+ from the ER by activating a G-protein-coupled receptor-phospholipase C complex that increased [IP3] (7). One way to reconcile present and previous (7) results is to propose that the phospholipase C inhibitor reduced [IP3] to low levels, so that the allosteric effect of 3O-C12 on IP3R was prevented. Further experiments will be required to determine the molecular details of 3O-C12 activation of IP3R and also whether other Ca2+ regulators were being affected.

3O-C12 Activates STIM1 and Increases cAMPcyto

Two other important findings of these studies were that 3O-C12 both activated STIM1 (as seen from increases in TIRF fluorescence in the plasma membrane) and triggered increases in cAMPcyto that were critical in mediating CFTR-dependent Cl and fluid secretion by airway epithelia. The 3O-C12-triggered increases in cAMPcyto (Epac H30 FRET ratio) and ICl were modest, comparable with the effects of low concentrations of forskolin. The effects of (Rp)-Br-cAMPS to reduce and IBMX to increase ICl responses to 3O-C12 were those expected if 3O-C12 were operating through cAMP/PKA.

Previous experiments in intestinal cells showed that complete emptying of the ER Ca2+ store by thapsigargin activated STIM1 and cAMP (15). The present data extend these observations by showing that partial (∼20%) reduction of CaER by 10 μm 3O-C12 also activated 3O-C12-triggered increases in STIM1 activity, adenylate cyclase, cAMP, PKA, and activation of CFTR. The conclusion that STIM1 activated adenylate cyclase rather than inhibiting phosphodiesterase is based on the observation that the phosphodiesterase inhibitor IBMX increased rather than decreased 3O-C12-stimulated ICl. 3O-C12-induced increases in Cacyto may also activate K+ channels, leading to hyperpolarization of the cells and increased electrical driving force for Cl exit through CFTR across the apical membrane. Activation of STIM1 is also expected to stimulate opening of the plasma membrane Ca2+ channel orai (47), which would cause sustained increases in Cacyto. Although 3O-C12 caused similar increases in Cacyto in Ca2+-containing and Ca2+-free solutions indicating that there was minimal activation of orai by 3O-C12 (7), further experiments are needed to test directly the role of orai activation in responses of airway epithelial cells to 3O-C12.

Store-operated cAMP Model Explains 3O-C12 Stimulation of CFTR-dependent Cl and Fluid Secretion by Airway Epithelia

A modification of the previously proposed store-operated adenylate cyclase-cAMP model (15) can explain the stimulatory effects of 3O-C12 on cAMPcyto and ICl by airway epithelial cells (Fig. 14). In control conditions, ICl is small because cAMPcyto and PKA activity are low, and CFTR is closed. As shown by the stimulatory effect of IBMX on ICl in the absence of other stimulation, cAMPcyto is maintained low by phosphodiesterase(s) that cleaves cAMP produced constitutively. CaER is maintained at a normally high level (likely >300 μm; see Refs. 40, 48) by the Ca2+-ATPase that counters the continual loss of Ca2+ through the IP3R or other Ca2+ leak (shown by effects of thapsigargin to reduce CaER in otherwise untreated cells). 3O-C12 directly activates the IP3R, leading to loss of Ca2+ from the ER and reduction of CaER. Based on ICl, IP3R patch clamp, and CaER measurements, it appears that the threshold concentration for 3O-C12-induced effects on cultured cells occurred at 10 μm with maximal effects at 50 μm. 3O-C12-induced reduction of CaER activates STIM1, which then migrates to the plasma membrane where it likely stimulates a still-to-be identified adenylate cyclase leading to accumulation of cAMP and activation of PKA and CFTR.

FIGURE 14.

FIGURE 14.

Stimulation of store-operated cAMP production and CFTR-dependent Cl secretion by 3O-C12 in airway epithelia. According to this model, 3O-C12 activates IP3R, reduces CaER, elevates Cacyto, and activates STIM1, cAMP production, PKA, CFTR, and Cl secretion by airway epithelia. See text for details.

The stimulatory effects of the high Kd Ca2+ chelator TPEN were also consistent with the model. As shown previously in intestinal cells, TPEN lowers CaER and increases cAMPcyto without affecting Cacyto (15). In CaLu-3 cells TPEN increased both cAMPcyto and ICl. Furthermore, TPEN and 3O-C12 appeared to modulate the same pool of Ca2+. Thus, TPEN, and 3O-C12 both increased ICl on their own, and effects of TPEN + 3O-C12 were less than additive compared with the effects of adding TPEN or 3O-C12 individually.

One apparent inconsistency between our results and the model was that 3O-C12 increased ICl in thapsigargin-treated cells (Fig. 4F), which should have produced maximal activation of STIM1 and adenylate cyclase. One possible explanation is that thapsigargin may not have released all the Ca2+ from the ER, and 3O-C12 caused a further small Ca2+ leak from the ER that then caused small reductions in CaER (Fig. 5C), increases in Cacyto (Fig. 4C), and activation of adenylate cyclase, cAMP, and Cl secretion (Fig. 4F). 3O-C12 may also have IP3R-Ca2+-independent effects to stimulate ICl. Further experiments will be required to resolve this issue.

In addition to effects on Cl secretion, 3O-C12-triggered decreases of CaER and increases in Cacyto and cAMPcyto could also contribute to multiple “downstream” effects of 3O-C12 in P. aeruginosa-infected patients, e.g. ER stress resulting from reduction in CaER (34, 49), IL8 secretion resulting from increases in Cacyto (33), mucous secretion resulting from increased Cacyto and cAMPcyto (45), and apoptosis (7) resulting from Ca2+ overload of mitochondria (50, 51). In CF airways, the effects of 3O-C12 on IP3R, CaER, Cacyto, STIM1, and cAMPcyto will lead not to increased Cl and fluid secretion to clear the bacterial product but instead to ER stress, secretions of IL8 and mucus, and apoptosis. Thus, the cross-kingdom effects of 3O-C12 on airway epithelial cell signaling could contribute to airway clearance in non-CF individuals and to pathogenesis in P. aeruginosa-infected CF patients.

Acknowledgments

We thank Dieter Gruenert for supply of CFBE41o and CFTR-corrected cells and Lauren Hum, Bharat Ravishankar, and Stanley Yen for help in performing imaging and electrophysiology.

*

This work was supported, in whole or in part, by National Institutes of Health Grants GM056328, MH059937, and PN2 EY018241. This work was also supported by Cystic Fibrosis Foundation Grants MACHEN06, MACHEN07, and ILLEK08, Cystic Fibrosis Research, Inc., and a Veterans Affairs Merit Review Award (to A. M. H.).

3

I. Maiellaro and A. M. Hofer, unpublished data.

2
The abbreviations used are:
CF
cystic fibrosis
CFTR
cystic fibrosis transmembrane regulator
ER
endoplasmic reticulum
3O-C12
N-(3-oxo-dodecanoyl)-S-homoserine lactone
TPEN
tetrakis-(2-pyridylmethyl)ethylenediamine
IBMX
isobutylmethylxanthine
IP3
inositol trisphosphate
IP3R
inositol trisphosphate receptor
CFP
cyan fluorescent protein.

REFERENCES

  • 1.Bjarnsholt T., Givskov M. (2007) Philos. Trans. R. Soc. Lond. B Biol. Sci. 362, 1213–1222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cooley M., Chhabra S. R., Williams P. (2008) Chem. Biol. 15, 1141–1147 [DOI] [PubMed] [Google Scholar]
  • 3.Davies D. G., Parsek M. R., Pearson J. P., Iglewski B. H., Costerton J. W., Greenberg E. P. (1998) Science 280, 295–298 [DOI] [PubMed] [Google Scholar]
  • 4.Fuqua C., Greenberg E. P. (2002) Nat. Rev. Mol. Cell Biol. 3, 685–695 [DOI] [PubMed] [Google Scholar]
  • 5.Pearson J. P., Gray K. M., Passador L., Tucker K. D., Eberhard A., Iglewski B. H., Greenberg E. P. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 197–201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Williams P. (2007) Microbiology 153, 3923–3938 [DOI] [PubMed] [Google Scholar]
  • 7.Shiner E. K., Terentyev D., Bryan A., Sennoune S., Martinez-Zaguilan R., Li G., Gyorke S., Williams S. C., Rumbaugh K. P. (2006) Cell. Microbiol. 8, 1601–1610 [DOI] [PubMed] [Google Scholar]
  • 8.Kravchenko V. V., Kaufmann G. F., Mathison J. C., Scott D. A., Katz A. Z., Grauer D. C., Lehmann M., Meijler M. M., Janda K. D., Ulevitch R. J. (2008) Science 321, 259–263 [DOI] [PubMed] [Google Scholar]
  • 9.Kravchenko V. V., Kaufmann G. F., Mathison J. C., Scott D. A., Katz A. Z., Wood M. R., Brogan A. P., Lehmann M., Mee J. M., Iwata K., Pan Q., Fearns C., Knaus U. G., Meijler M. M., Janda K. D., Ulevitch R. J. (2006) J. Biol. Chem. 281, 28822–28830 [DOI] [PubMed] [Google Scholar]
  • 10.DiMango E., Zar H. J., Bryan R., Prince A. (1995) J. Clin. Invest. 96, 2204–2210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Smith R. S., Fedyk E. R., Springer T. A., Mukaida N., Iglewski B. H., Phipps R. P. (2001) J. Immunol. 167, 366–374 [DOI] [PubMed] [Google Scholar]
  • 12.Smith R. S., Kelly R., Iglewski B. H., Phipps R. P. (2002) J. Immunol. 169, 2636–2642 [DOI] [PubMed] [Google Scholar]
  • 13.Li H., Wang L., Ye L., Mao Y., Xie X., Xia C., Chen J., Lu Z., Song J. (2009) Med. Microbiol. Immunol. 198, 113–121 [DOI] [PubMed] [Google Scholar]
  • 14.Jahoor A., Patel R., Bryan A., Do C., Krier J., Watters C., Wahli W., Li G., Williams S. C., Rumbaugh K. P. (2008) J. Bacteriol. 190, 4408–4415 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lefkimmiatis K., Srikanthan M., Maiellaro I., Moyer M. P., Curci S., Hofer A. M. (2009) Nat. Cell Biol. 11, 433–442 [DOI] [PubMed] [Google Scholar]
  • 16.Luik R. M., Lewis R. S. (2007) Trends Mol. Med. 13, 103–107 [DOI] [PubMed] [Google Scholar]
  • 17.Kunzelmann K., Scheidt K., Scharf B., Ousingsawat J., Schreiber R., Wainwright B., McMorran B. (2006) FASEB J. 20, 545–546 [DOI] [PubMed] [Google Scholar]
  • 18.Muanprasat C., Sonawane N. D., Salinas D., Taddei A., Galietta L. J., Verkman A. S. (2004) J. Gen. Physiol. 124, 125–137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Thiagarajah J. R., Song Y., Haggie P. M., Verkman A. S. (2004) FASEB J. 18, 875–877 [DOI] [PubMed] [Google Scholar]
  • 20.Treiman M., Caspersen C., Christensen S. B. (1998) Trends Pharmacol. Sci. 19, 131–135 [DOI] [PubMed] [Google Scholar]
  • 21.Shen B. Q., Finkbeiner W. E., Wine J. J., Mrsny R. J., Widdicombe J. H. (1994) Am. J. Physiol. 266, L493–L501 [DOI] [PubMed] [Google Scholar]
  • 22.Illek B., Fu Z., Schwarzer C., Banzon T., Jalickee S., Miller S. S., Machen T. E. (2008) Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L531–L542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Illek B., Maurisse R., Wahler L., Kunzelmann K., Fischer H., Gruenert D. C. (2008) Cell. Physiol. Biochem. 22, 57–68 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Schwarzer C., Fischer H., Kim E. J., Barber K. J., Mills A. D., Kurth M. J., Gruenert D. C., Suh J. H., Machen T. E., Illek B. (2008) Free Radic. Biol. Med. 45, 1653–1662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Joo N. S., Saenz Y., Krouse M. E., Wine J. J. (2002) J. Biol. Chem. 277, 28167–28175 [DOI] [PubMed] [Google Scholar]
  • 26.Joo N. S., Wu J. V., Krouse M. E., Saenz Y., Wine J. J. (2001) Am. J. Physiol. Lung Cell. Mol. Physiol. 281, L458–L468 [DOI] [PubMed] [Google Scholar]
  • 27.Choi J. Y., Khansaheb M., Joo N. S., Krouse M. E., Robbins R. C., Weill D., Wine J. J. (2009) J. Clin. Invest. 119, 1189–1200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Choi J. Y., Joo N. S., Krouse M. E., Wu J. V., Robbins R. C., Ianowski J. P., Hanrahan J. W., Wine J. J. (2007) J. Clin. Invest. 117, 3118–3127 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Taylor C. W., Rahman T., Tovey S. C., Dedos S. G., Taylor E. J., Velamakanni S. (2009) Immunol. Rev. 231, 23–44 [DOI] [PubMed] [Google Scholar]
  • 30.Cheung K. H., Shineman D., Müller M., Cárdenas C., Mei L., Yang J., Tomita T., Iwatsubo T., Lee V. M., Foskett J. K. (2008) Neuron 58, 871–883 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ionescu L., Cheung K. H., Vais H., Mak D. O., White C., Foskett J. K. (2006) J. Physiol. 573, 645–662 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.White C., Li C., Yang J., Petrenko N. B., Madesh M., Thompson C. B., Foskett J. K. (2005) Nat. Cell Biol. 7, 1021–1028 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Fu Z., Bettega K., Carroll S., Buchholz K. R., Machen T. E. (2007) Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L353–L364 [DOI] [PubMed] [Google Scholar]
  • 34.Hybiske K., Fu Z., Schwarzer C., Tseng J., Do J., Huang N., Machen T. E. (2007) Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L1250–L1260 [DOI] [PubMed] [Google Scholar]
  • 35.Schwarzer C., Fu Z., Fischer H., Machen T. E. (2008) J. Biol. Chem. 283, 27144–27153 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Grynkiewicz G., Poenie M., Tsien R. Y. (1985) J. Biol. Chem. 260, 3440–3450 [PubMed] [Google Scholar]
  • 37.Gerbino A., Ruder W. C., Curci S., Pozzan T., Zaccolo M., Hofer A. M. (2005) J. Cell Biol. 171, 303–312 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Ponsioen B., Zhao J., Riedl J., Zwartkruis F., van der Krogt G., Zaccolo M., Moolenaar W. H., Bos J. L., Jalink K. (2004) EMBO Rep. 5, 1176–1180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Palmer A. E., Jin C., Reed J. C., Tsien R. Y. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 17404–17409 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Palmer A. E., Tsien R. Y. (2006) Nat. Protoc. 1, 1057–1065 [DOI] [PubMed] [Google Scholar]
  • 41.Miyawaki A., Griesbeck O., Heim R., Tsien R. Y. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 2135–2140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mak D. O., White C., Ionescu L., Foskett J. K. (2005) in Methods in Calcium Signaling Research (Putney J. W., Jr., ed) pp. 203–229, CRC Press, Inc., Boca Raton, FL [Google Scholar]
  • 43.Gadsby D. C., Nairn A. C. (1999) Physiol. Rev. 79, S77-S107 [DOI] [PubMed] [Google Scholar]
  • 44.Hwang T. C., Sheppard D. N. (2009) J. Physiol. 587, 2151–2161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Imamura Y., Yanagihara K., Mizuta Y., Seki M., Ohno H., Higashiyama Y., Miyazaki Y., Tsukamoto K., Hirakata Y., Tomono K., Kadota J., Kohno S. (2004) Antimicrob. Agents Chemother. 48, 3457–3761 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Machen T. E. (2006) Am. J. Physiol. Cell. Physiol. 291, C218–C230 [DOI] [PubMed] [Google Scholar]
  • 47.Hogan P. G., Lewis R. S., Rao A. (2010) Annu. Rev. Immunol. 28, 491–533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Oakes S. A., Scorrano L., Opferman J. T., Bassik M. C., Nishino M., Pozzan T., Korsmeyer S. J. (2005) Proc. Natl. Acad. Sci. U.S.A. 102, 105–110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Zhang K., Kaufman R. J. (2006) Neurology 66, S102–S109 [DOI] [PubMed] [Google Scholar]
  • 50.Giorgi C., Romagnoli A., Pinton P., Rizzuto R. (2008) Curr. Mol. Med. 8, 119–130 [DOI] [PubMed] [Google Scholar]
  • 51.Pinton P., Giorgi C., Siviero R., Zecchini E., Rizzuto R. (2008) Oncogene 27, 6407–6418 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology

RESOURCES